Drug intelligence / Profile preview

Revanesse Lips+

Development stage: Unknown
Lead developer: Prollenium Medical Technologies
Administration: Intradermal

Overview

Revanesse Lips+ (PN40082) is a cross-linked hyaluronic acid (HA) dermal filler developed by Prollenium Medical Technologies. It is an injectable gel indicated for submucosal implantation for lip augmentation and the correction of perioral rhytids in adults over the age of 21. The product is manufactured using a proprietary cross-linking technology (Thixofix) that creates a smooth, monophasic gel designed for ease of injection and natural-looking results. It typically contains 0.3% lidocaine hydrochloride to enhance patient comfort during the procedure. Clinical studies have demonstrated its safety and efficacy, showing non-inferiority to other market-leading HA fillers like Restylane Silk.

Brand names: Revanesse Lips+
Other names: Revanesse Lips Plus

Beyond the preview

Go deeper on Revanesse Lips+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revanesse Lips+.

Explore the full profile